+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Enzalutamide Drugs Market - Global Forecast 2026-2032- Product Image
Enzalutamide Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Enzalutamide Drugs Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6127215
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Enzalutamide Drugs Market is projected to reach USD 7.50 Billion in 2026. It is expected to continue growing at a CAGR of 8.71%, reaching USD 12.51 Billion by 2032.

Enzalutamide Drugs: Executive Overview

Enzalutamide is an androgen-receptor signaling inhibitor used primarily in the treatment of prostate cancer. Its clinical role is shaped by disease stage, prior therapy, biomarker assessment, treatment guidelines, reimbursement policy, and the ability of healthcare systems to deliver long-term oncology care. The market is therefore influenced by both therapeutic evidence and the broader shift toward personalized, multidisciplinary cancer management.

How Prostate Cancer Care Is Transforming

Prostate cancer management is moving toward earlier risk stratification, treatment sequencing, and combination approaches tailored to disease biology and patient health. Greater use of imaging, genomic testing, real-world evidence, and shared decision-making is refining treatment selection. At the same time, oral oncology creates opportunities for outpatient care but increases the importance of adherence monitoring, drug-interaction review, toxicity management, and patient support.

Artificial Intelligence Strengthens Treatment Decisions and Delivery

Artificial intelligence is increasingly relevant across prostate cancer pathways, including imaging interpretation, pathology support, risk classification, clinical-trial matching, and identification of patients who may benefit from particular treatment sequences. It can also support adherence monitoring, adverse-event detection, and analysis of real-world outcomes. However, clinical validation, transparency, data quality, privacy, and equitable access remain essential before AI-supported tools can be incorporated consistently into routine enzalutamide treatment decisions.

Regional Insights Across Prostate Cancer Care Systems

North America combines advanced oncology infrastructure, broad access to specialist care, and extensive use of evidence-based treatment pathways, while affordability and payer authorization remain important considerations. Europe is shaped by national health technology assessment, country-specific reimbursement, and coordinated clinical guidelines. Asia-Pacific presents a varied landscape, with sophisticated centers alongside uneven diagnostic and treatment access. Latin America continues to expand specialist oncology capacity but faces differences in public coverage, affordability, and medicine distribution. The Middle East is investing in modern cancer centers and referral networks, although access varies by country. Africa faces substantial gaps in screening, diagnosis, specialist capacity, and treatment continuity, making health-system strengthening central to effective use of advanced prostate cancer therapies.

Group-Level Priorities: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets require stronger cross-border cooperation, oncology workforce development, and more consistent access to diagnostics and oral cancer medicines. BRICS countries show substantial variation in infrastructure, reimbursement, domestic pharmaceutical capability, and treatment accessibility, with opportunities to improve guideline implementation and outcomes research. The European Union emphasizes coordinated evidence assessment while retaining national reimbursement decisions. G7 health systems generally have mature oncology networks but continue to address cost-effectiveness, aging populations, and care disparities. GCC countries are strengthening specialist services and centralized referral models. NATO members span diverse health systems, making shared clinical standards, resilient supply chains, and continuity of care important priorities.

Country-Level Considerations for Enzalutamide Access

Australia and Canada rely on structured public reimbursement and specialist pathways, with access influenced by national and provincial or territorial policy. Brazil and Mexico face differences between private and public oncology provision and continued challenges in geographic coverage. China and India are expanding oncology capacity while addressing regional disparities, affordability, and diagnostic consistency. Japan, South Korea, Singapore, and other advanced Asian systems emphasize guideline-based care, aging-population needs, and monitoring of treatment tolerability. France, Germany, Italy, Spain, and the United Kingdom apply national or regional assessment and reimbursement frameworks that influence prescribing pathways. Russia’s access environment is shaped by domestic policy, procurement, and oncology infrastructure. Across all listed countries, treatment continuity depends on specialist availability, patient support, medicine affordability, and reliable supply.

Actions for Industry Leaders: Improve Value, Access, and Evidence

Industry leaders should align evidence generation with clinically meaningful outcomes, including overall survival, quality of life, treatment persistence, and outcomes across patient subgroups. They should support appropriate use through education on treatment sequencing, interactions, adherence, and adverse-event management. Partnerships with providers and payers can help develop patient-assistance and access models that reflect local health-system needs. Investments in interoperable data, validated AI applications, pharmacovigilance, and transparent real-world evidence can strengthen clinical confidence. Supply-chain resilience and responsible engagement with regulators are also essential for dependable treatment availability.

Research Methodology for the Executive Summary

This executive summary uses the supplied market definition-enzalutamide drugs-and synthesizes established clinical, regulatory, healthcare-delivery, and policy considerations relevant to the therapy area. The assessment is organized across global regions, economic and political groupings, and specified countries to identify differences in access, infrastructure, reimbursement, and treatment practice. It intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific analysis. Interpretations should be validated against current clinical guidelines, regulatory decisions, local reimbursement rules, and peer-reviewed evidence before operational use.

Conclusion: Build Patient-Centered, Evidence-Led Access

The enzalutamide treatment landscape is defined by advances in prostate cancer stratification, evolving treatment sequences, and uneven health-system capacity. Sustainable progress will depend on combining robust clinical evidence with equitable access, adherence support, specialist expertise, reliable supply, and responsible use of digital and AI-enabled tools. Leaders that prioritize patient outcomes, transparent evidence, and locally appropriate delivery models will be better positioned to improve the quality and consistency of prostate cancer care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Enzalutamide Drugs Market, by Brand Type
7.1. Introduction
7.2. Branded
7.3. Generic
8. Enzalutamide Drugs Market, by Indication
8.1. Introduction
8.2. Metastatic Castration-Resistant Prostate Cancer
8.3. Metastatic Hormone-Sensitive Prostate Cancer
8.4. Non-Metastatic Castration-Resistant Prostate Cancer
9. Enzalutamide Drugs Market, by Formulation
9.1. Introduction
9.2. Capsules
9.3. Solution
9.4. Tablet
10. Enzalutamide Drugs Market, by Dosage Strength
10.1. Introduction
10.2. 20 Milligram
10.3. 40 Milligram
11. Enzalutamide Drugs Market, by End User
11.1. Introduction
11.2. Hospitals
11.2.1. Private Hospitals
11.2.2. Public Hospitals
11.3. Retail Pharmacies
11.4. Specialized Cancer Centers
12. Enzalutamide Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Enzalutamide Drugs Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Enzalutamide Drugs Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Enzalutamide Drugs Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Aarti Pharmalabs Limited
17.2. Aprazer Healthcare Private Limited
17.3. Astellas Pharma Inc.
17.4. BDR Pharmaceuticals International Private Limited
17.5. Cipla Limited
17.6. Dr. Reddy’s Laboratories Limited
17.7. Glenmark Pharmaceuticals Limited
17.8. Hetero Healthcare Limited
17.9. Hunan Huateng Pharmaceutical Co., Ltd.
17.10. Intas Pharmaceuticals Limited
17.11. Laurus Labs Limited
17.12. MSN Laboratories Private Limited
17.13. Pfizer Inc.
17.14. RPG Life Sciences Limited
17.15. Shilpa Medicare Limited
17.16. Shivalik Rasayan Limited
17.17. Sun Pharmaceutical Industries Limited
17.18. Viatris Inc.
17.19. Zaklady Farmaceutyczne Polpharma S.A.
17.20. Zydus Lifesciences Limited
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Enzalutamide Drugs Market, Years Considered for the Study
FIGURE 2. Global Enzalutamide Drugs Market, Research Design
FIGURE 3. Global Enzalutamide Drugs Market, Research Framework
FIGURE 4. Global Enzalutamide Drugs Market, Data Triangulation
FIGURE 5. Global Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Enzalutamide Drugs Market Size, by Brand Type, 2025 vs 2032 (%)
FIGURE 7. Global Enzalutamide Drugs Market Size, by Brand Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Enzalutamide Drugs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Enzalutamide Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Enzalutamide Drugs Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 11. Global Enzalutamide Drugs Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Enzalutamide Drugs Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 13. Global Enzalutamide Drugs Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Enzalutamide Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Enzalutamide Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Enzalutamide Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Enzalutamide Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Enzalutamide Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Enzalutamide Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Enzalutamide Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Enzalutamide Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Enzalutamide Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Enzalutamide Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Enzalutamide Drugs Market Segmentation & Coverage
TABLE 2. Global Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 4. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 11. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Metastatic Hormone-Sensitive Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Metastatic Hormone-Sensitive Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Metastatic Hormone-Sensitive Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Non-Metastatic Castration-Resistant Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Non-Metastatic Castration-Resistant Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Non-Metastatic Castration-Resistant Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 21. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Solution Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Solution Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Solution Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 31. Global 20 Milligram Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global 20 Milligram Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global 20 Milligram Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global 40 Milligram Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global 40 Milligram Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global 40 Milligram Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 38. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Public Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Public Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Public Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Specialized Cancer Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Specialized Cancer Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Specialized Cancer Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 54. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Enzalutamide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Enzalutamide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 69. North America Enzalutamide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. North America Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 71. North America Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 72. North America Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 73. North America Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 74. North America Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. North America Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 76. North America Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Latin America Enzalutamide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Latin America Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 79. Latin America Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 80. Latin America Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 81. Latin America Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 82. Latin America Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. Latin America Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 84. Latin America Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 85. Europe Enzalutamide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Europe Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 87. Europe Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 88. Europe Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 89. Europe Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 90. Europe Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. Europe Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 92. Europe Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. Middle East Enzalutamide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Middle East Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 95. Middle East Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 96. Middle East Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 97. Middle East Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 98. Middle East Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Middle East Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 100. Middle East Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 101. Africa Enzalutamide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Africa Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 103. Africa Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 104. Africa Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 105. Africa Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 106. Africa Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. Africa Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 108. Africa Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. Global Enzalutamide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. ASEAN Enzalutamide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. ASEAN Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 112. ASEAN Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 113. ASEAN Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 114. ASEAN Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 115. ASEAN Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. ASEAN Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 117. ASEAN Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. GCC Enzalutamide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. GCC Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 120. GCC Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 121. GCC Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 122. GCC Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 123. GCC Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. GCC Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 125. GCC Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. European Union Enzalutamide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. European Union Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 128. European Union Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 129. European Union Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 130. European Union Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 131. European Union Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. European Union Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 133. European Union Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. BRICS Enzalutamide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. BRICS Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 136. BRICS Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 137. BRICS Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 138. BRICS Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 139. BRICS Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. BRICS Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 141. BRICS Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. G7 Enzalutamide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. G7 Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 144. G7 Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 145. G7 Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 146. G7 Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 147. G7 Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. G7 Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 149. G7 Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. NATO Enzalutamide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. NATO Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 152. NATO Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 153. NATO Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 154. NATO Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 155. NATO Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. NATO Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 157. NATO Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. Global Enzalutamide Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 159. United States Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 160. United States Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 161. United States Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 162. United States Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 163. United States Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 164. United States Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. United States Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 166. United States Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Canada Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 168. Canada Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 169. Canada Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. Canada Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 171. Canada Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 172. Canada Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. Canada Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 174. Canada Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. Mexico Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 176. Mexico Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 177. Mexico Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 178. Mexico Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 179. Mexico Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 180. Mexico Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Mexico Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 182. Mexico Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. Brazil Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 184. Brazil Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 185. Brazil Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 186. Brazil Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 187. Brazil Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 188. Brazil Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. Brazil Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 190. Brazil Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. United Kingdom Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 192. United Kingdom Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 193. United Kingdom Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 194. United Kingdom Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 195. United Kingdom Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 196. United Kingdom Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. United Kingdom Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 198. United Kingdom Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. Germany Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 200. Germany Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 201. Germany Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 202. Germany Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 203. Germany Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 204. Germany Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Germany Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 206. Germany Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. France Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 208. France Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 209. France Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 210. France Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 211. France Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 212. France Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. France Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 214. France Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. Russia Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 216. Russia Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 217. Russia Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 218. Russia Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 219. Russia Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 220. Russia Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. Russia Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 222. Russia Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. Italy Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 224. Italy Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 225. Italy Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 226. Italy Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 227. Italy Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 228. Italy Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. Italy Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 230. Italy Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 231. Spain Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 232. Spain Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 233. Spain Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 234. Spain Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 235. Spain Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 236. Spain Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. Spain Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 238. Spain Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. China Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 240. China Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 241. China Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 242. China Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 243. China Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 244. China Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. China Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 246. China Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. India Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 248. India Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 249. India Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 250. India Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 251. India Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 252. India Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 253. India Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 254. India Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. Japan Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 256. Japan Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 257. Japan Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 258. Japan Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 259. Japan Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 260. Japan Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. Japan Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 262. Japan Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Australia Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 264. Australia Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 265. Australia Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 266. Australia Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 267. Australia Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 268. Australia Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 269. Australia Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 270. Australia Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 271. South Korea Enzalutamide Drugs Market Size, 2017-2032 (USD Million)
TABLE 272. South Korea Enzalutamide Drugs Market Size, by Brand Type, 2017-2032 (USD Million)
TABLE 273. South Korea Enzalutamide Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 274. South Korea Enzalutamide Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 275. South Korea Enzalutamide Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 276. South Korea Enzalutamide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 277. South Korea Enzalutamide Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 278. South Korea Enzalutamide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 279. Global Enzalutamide Drugs Market Share, by Key Player, 2025
TABLE 280. Global Enzalutamide Drugs Market, Key Experts

Companies Mentioned

  • Aarti Pharmalabs Limited
  • Aprazer Healthcare Private Limited
  • Astellas Pharma Inc.
  • BDR Pharmaceuticals International Private Limited
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • Glenmark Pharmaceuticals Limited
  • Hetero Healthcare Limited
  • Hunan Huateng Pharmaceutical Co., Ltd.
  • Intas Pharmaceuticals Limited
  • Laurus Labs Limited
  • MSN Laboratories Private Limited
  • Pfizer Inc.
  • RPG Life Sciences Limited
  • Shilpa Medicare Limited
  • Shivalik Rasayan Limited
  • Sun Pharmaceutical Industries Limited
  • Viatris Inc.
  • Zakłady Farmaceutyczne Polpharma S.A.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Enzalutamide Tablets Market - Global Forecast 2026-2032 - Product Image

Enzalutamide Tablets Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Enzalutamide Soft Capsules Market - Global Forecast 2026-2032 - Product Image

Enzalutamide Soft Capsules Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Non-Metastatic Prostate Cancer (NmPC) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Non-Metastatic Prostate Cancer (NmPC) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 230 Pages
  • Global
From
Metastatic Prostate Cancer - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Metastatic Prostate Cancer - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 432 Pages
  • Global
From
Prostate Cancer Therapeutics Market - Product Image

Prostate Cancer Therapeutics Market

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.